Liquid biopsy market expected to reach $11.3 billion by 2029, with key drivers and challenges.

From GlobeNewswire: 2024-05-27 08:30:00

The liquid biopsy market was valued at $6.4 billion in 2024, expected to reach $11.3 billion by 2029 with a CAGR of 11.9%. Liquid biopsies offer an effective method for cancer detection, therapy selection, and monitoring. While there are challenges with sensitivity and specificity, the market continues to evolve with growing adoption and recognition of its advantages over traditional biopsies.

Key market drivers include the benefits of liquid biopsy over conventional procedures and the significance of companion diagnostics. Assay kits hold the largest market share, while circulating tumor cells dominate in terms of circulating biomarkers. Cancer applications make up the majority of liquid biopsy usage, with broad applicability across various cancer types.

Asia Pacific is projected to show the highest CAGR in the liquid biopsy market, driven by government initiatives to address cancer burden and improve healthcare access. Leading players in the market include Natera, QIAGEN, Myriad Genetics, and Illumina. The market is segmented by product & service, circulating biomarker, clinical application, technology, application, sample type, end user, and region, providing a comprehensive overview of the industry.



Read more at GlobeNewswire: Liquid Biopsy Market is Expected to Reach $11.3 billion |